이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 육종에서 항암제인 페포서팁과 병용한 저용량 일반 화학요법(리포좀 독소루비신) 테스트

2026년 11월 13일 업데이트: National Cancer Institute (NCI)

전이성 평활근육종 및 기타 연조직 육종 환자를 대상으로 한 Peposertib(M3814) 및 저용량 리포솜 독소루비신(Doxil®)의 1상 연구

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.

연구 개요

상세 설명

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of peposertib in combination with low-dose pegylated liposomal doxorubicin hydrochloride (liposomal doxorubicin) as evaluated by the dose-limiting toxicity (DLT) rate at each tested dose level.

II. To determine the recommended phase 2 dose (RP2D) of liposomal doxorubicin and peposertib combination and determine the maximal tolerated dose (MTD) if identified.

SECONDARY OBJECTIVE:

I. To assess the pharmacokinetics of peposertib and liposomal doxorubicin used in combination with each other.

CORRELATIVE OBJECTIVES:

I. To test the hypothesis that soft tissue sarcomas (STS) with homologous recombination deficiency (HRD) like leiomyosarcomas (LMS) will be more susceptible to DNA-protein kinase inhibitor (PKi) in combination with low-dose liposomal doxorubicin.

II. To test the hypothesis that gammaH2AX and pNBS1 can be used as pharmacodynamic biomarkers of response to DNA-PKi in combination with low-dose liposomal doxorubicin.

III. To test the hypothesis that disease activity correlates with circulating tumor DNA levels in the plasma.

OUTLINE: This is a dose-escalation study of peposertib and liposomal doxorubicin.

Patients receive peposertib orally (PO) twice daily (BID) on days 1-28 of each cycle and liposomal doxorubicin intravenously (IV) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial. Patients also undergo tissue biopsy and echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and on the trial.

Patients are followed for 30 days after removal from study or until death, whichever occurs first.

연구 유형

중재적

등록 (추정된)

30

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Los Angeles, California, 미국, 90033
        • 모병
        • USC / Norris Comprehensive Cancer Center
        • 수석 연구원:
          • Mark Agulnik
        • 연락하다:
          • Site Public Contact
          • 전화번호: 323-865-0451
      • Los Angeles, California, 미국, 90033
        • 모병
        • Los Angeles General Medical Center
        • 수석 연구원:
          • Mark Agulnik
        • 연락하다:
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • 모병
        • UCHealth University of Colorado Hospital
        • 수석 연구원:
          • Breelyn A. Wilky
        • 연락하다:
          • Site Public Contact
          • 전화번호: 720-848-0650
    • Florida
      • Miami, Florida, 미국, 33136
        • 모병
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • 수석 연구원:
          • Emily E. Jonczak
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • 모집하지 않고 적극적으로
        • University of Chicago Comprehensive Cancer Center
      • New Lenox, Illinois, 미국, 60451
        • 모집하지 않고 적극적으로
        • UC Comprehensive Cancer Center at Silver Cross
      • Orland Park, Illinois, 미국, 60462
        • 모집하지 않고 적극적으로
        • University of Chicago Medicine-Orland Park
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • 모병
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • 연락하다:
        • 수석 연구원:
          • H. Catherine Wilbur
      • Bethesda, Maryland, 미국, 20892
        • 모병
        • National Cancer Institute Developmental Therapeutics Clinic
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-411-1222
        • 수석 연구원:
          • A P. Chen
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • 모병
        • Dana-Farber Cancer Institute
        • 연락하다:
          • Site Public Contact
          • 전화번호: 877-442-3324
        • 수석 연구원:
          • Candace L. Haddox
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 정지된
        • University of Michigan Rogel Cancer Center
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Washington University School of Medicine
        • 수석 연구원:
          • Mia C. Weiss
        • 연락하다:
      • St Louis, Missouri, 미국, 63129
        • 모병
        • Siteman Cancer Center-South County
        • 수석 연구원:
          • Mia C. Weiss
        • 연락하다:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, 미국, 15232
        • 모병
        • UPMC Hillman Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 412-647-8073
        • 수석 연구원:
          • Melissa A. Burgess
    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • UT MD Anderson Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Michael S. Nakazawa
    • Virginia
      • Charlottesville, Virginia, 미국, 22908

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Patients must have histologically confirmed sarcoma that is metastatic or unresectable and for which there is no known curative treatment

  • Patients must have histologic diagnosis of leiomyosarcoma (LMS) or selected soft tissue sarcomas (myxofibrosarcoma [MFS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma, or dedifferentiated liposarcoma [DDLPS]). Pathology review and confirmation of diagnosis will occur at the site enrolling the patient on this study. If the pathology has previously been reviewed by another site participating in the study, the diagnosis does not need to be re-reviewed at the enrolling site

  • Patients must have evaluable disease that is amenable to biopsy

  • Patients must have been treated with at least 1 prior line of therapy. Prior anthracycline use is permitted as long as the cumulative dose prior to enrollment does not exceed 360 mg/m^2

  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of peposertib (M3814) in combination with liposomal doxorubicin in patients < 18 years of age, children are excluded from this study

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Absolute neutrophil count >= 1,500/mcL

  • Platelets >= 100,000/mcL

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN

  • Hemoglobin >= 8 g/dL

  • Glomerular filtration rate (GFR) >= 51 mL/min/1.73 m^2 (per institutional estimate based on creatinine level)

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and clinical symptoms are stable while off steroid support

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with known history of clinically significant cardiac disease, or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

  • Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

    • Female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 3 months after the last dose of peposertib (M3814) and 6 months after the last dose of liposomal doxorubicin
  • Male patients of reproductive potential must agree to avoid impregnating a partner while receiving study drug and for 3 months after the last dose of peposertib (M3814) and 6 months after the last dose of liposomal doxorubicin by complying with adequate methods of contraception

    • Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient
  • Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible

Exclusion Criteria:

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia

  • Prior palliative radiotherapy within 14 days of cycle 1 day 1 and prior definitive radiotherapy within 42 days of cycle 1 day 1. Adverse effects of radiation therapy must resolve to baseline prior to cycle 1 day 1

  • Patients who are receiving any other investigational agents

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to peposertib (M3814) or other agents used in study

  • Patients who cannot discontinue concomitant medications or herbal supplements that are strong inhibitors or strong inducers of cytochrome P450 (CYP) isoenzymes CYP3A4/5, CYP2C9, and CYP2C19. Participants who cannot discontinue substrates with a narrow therapeutic index that are metabolized by CYP1A2, CYP2B6, CYP2C8, and CYP3A4/5 are ineligible. Patients may confer with the study doctor to determine if alternative medications can be used. The following categories of medications and herbal supplements must be discontinued for at least the specified period of time before the patient can be treated:

    • Strong inducers of CYP3A4/5 and CYP2C19: >= 3 weeks prior to study treatment
    • Strong inhibitors of CYP3A4/5 and CYP2C19: >= 1 week prior to study treatment
    • Substrates of CYP3A4/5 with a narrow therapeutic index: >= 1 day prior to study treatment
    • Strong inhibitors of CYP2C9: >= 1 week prior to study treatment
  • Patients who cannot discontinue concomitant proton-pump inhibitors (PPIs). Patients may confer with the study doctor to determine if such medications can be discontinued. These must be discontinued >= 5 days prior to study treatment. Patients do not need to discontinue calcium carbonate

  • Patients with left ventricular ejection fraction (LVEF) measurement below the institutional lower limit of normal (LLN) are excluded

  • Patients with uncontrolled intercurrent illness

  • Patients who cannot swallow tablets whole

  • Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are not eligible

  • Pregnant women are excluded from this study because peposertib (M3814) is an adenosine triphosphate (ATP)-competitive inhibitor of DNA-protein kinase catalytic subunit (PKcs) with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with peposertib (M3814), breastfeeding should be discontinued if the mother is treated with peposertib (M3814). These potential risks may also apply to other agents used in this study

  • Patients may not have received prior treatment with a DNA-protein kinase (PK) inhibitor

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment (peposertib, liposomal doxorubicin)

Patients receive peposertib PO BID on days 1-28 of each cycle and liposomal doxorubicin IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo blood sample collection and CT or MRI throughout the trial. Patients also undergo tissue biopsy and ECHO or MUGA during screening and on the trial.

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Undergo ECHO

다른 이름들:
  • 심초음파
  • EC

Undergo MUGA

다른 이름들:
  • 혈액 풀 스캔
  • 평형 방사성핵종 혈관조영술
  • 게이티드 혈액 풀 이미징
  • 무가
  • 방사성핵종 뇌실조영술
  • RNVG
  • SYMA 스캐닝
  • 동기화된 다중 게이트 수집 스캐닝
  • 무가 스캔
  • 다중 게이트 획득 스캔
  • 방사성핵종 뇌실도 스캔
  • 게이트 하트 풀 스캔
  • RNV 스캔

Undergo CT scan

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Given IV

다른 이름들:
  • ATI-0918
  • Caelyx
  • 독실
  • 독실렌
  • 독소루비신 HCl 리포좀
  • 두오메이수
  • 에바셋
  • 리포독스
  • 리포솜 아드리아마이신
  • 리포솜 캡슐화된 독소루비신
  • 페길화된 독소루비신 HCl 리포좀
  • S-리포좀 독소루비신
  • 스텔스 리포솜 독소루비신
  • TLC D-99
  • Dox-SL
  • 독소루비신 HCl 리포솜
  • 독소루비신 염산염 리포솜
  • 리포독스 50
  • 리포솜 독소루비신 염산염
  • 페길화된 리포솜 독소루비신
  • 리포솜 독소루비신

Undergo tissue biopsy

다른 이름들:
  • 비엑스
  • 생검_유형
  • 생검

Given PO

다른 이름들:
  • MSC2490484A
  • 3-피리다진메탄올, 알파-(2-클로로-4-플루오로-5-(7-(4-모르폴리닐)-4-퀴나졸리닐)페닐)-6-메톡시-, (alphaS)-
  • 남 3814
  • M-3814
  • M3814
  • MSC 2490484A
  • MSC-2490484A
  • 네디저팁

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Dose limiting toxicity (DLT) rate
기간: Up to 28 days

The number and type of DLT seen at each dose level will be provided. The adverse events (AEs) will also be summarized by AE type and the maximum grade of the AE experienced by the patient for each dose level. DLT will be used to determine the recommended phase 2 dose of study drugs.

Up to 28 days

2차 결과 측정

결과 측정
측정값 설명
기간
Incidence of adverse events
기간: Up to 30 days after the end of study treatment

AEs will be assessed using Common Terminology Criteria for Adverse Events version 5.

Up to 30 days after the end of study treatment
Objective response rate
기간: Up to 28 days

Assessed with Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.

Up to 28 days
Progression free survival
기간: From study enrollment until disease progression (determined by RECIST v1.1) or death due to any cause, whichever occurs first

The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Patients who are alive at the time of analysis without a documented disease progression will be censored at the time of their last tumor evaluation.

From study enrollment until disease progression (determined by RECIST v1.1) or death due to any cause, whichever occurs first
Homologous recombination deficiency (HRD) status
기간: Up to 1 year

Will be defined by HRD score and mutational signature analysis.

Up to 1 year
Deoxyribonucleic acid damage repair activity
기간: Up to 1 year

Will be defined by gammaH2AX and NBS1 S343 phosphorylation based on the National Clinical Laboratory Network DDR3 assay.

Up to 1 year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Candace L Haddox, Dana-Farber - Harvard Cancer Center LAO

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 2월 6일

기본 완료 (추정된)

2027년 5월 3일

연구 완료 (추정된)

2027년 5월 3일

연구 등록 날짜

최초 제출

2023년 2월 2일

QC 기준을 충족하는 최초 제출

2023년 2월 2일

처음 게시됨 (실제)

2023년 2월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 13일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다